Literature DB >> 6352644

Ceftazidime in the treatment of febrile immunosuppressed children.

P J Darbyshire, P J Williamson, S J Pedler, D C Speller, M G Mott, A Oakhill.   

Abstract

We carried out a pilot study using ceftazidime alone in the treatment of febrile, neutropenic children. A total of 16 episodes were treated before the study was re-evaluated and tobramycin was added. Nineteen episodes have now been treated with a combination of ceftazidime and tobramycin. Of the first group, seven episodes failed to respond to ceftazidime; in five resistant or only partially sensitive organisms were thought to be the cause of failure. The most serious problem was our inability to predict two severe staphylococcal infections only partially sensitive to ceftazidime. These initial findings led us to add tobramycin to the regimen and to conclude that ceftazidime is not an appropriate antibiotic as a single agent in this group of patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352644     DOI: 10.1093/jac/12.suppl_a.357

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins.

Authors:  D Kalman; S L Barriere
Journal:  Tex Heart Inst J       Date:  1990

2.  Problems associated with indwelling central venous catheters.

Authors:  P J Darbyshire; N C Weightman; D C Speller
Journal:  Arch Dis Child       Date:  1985-02       Impact factor: 3.791

Review 3.  Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy.

Authors:  J W Hathorn; M Rubin; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

Review 4.  [Ceftazidime in the treatment of pediatric infections--a review].

Authors:  D Adam; R Tolxdorff-Neutzling
Journal:  Infection       Date:  1987       Impact factor: 3.553

5.  [Experiences with ceftazidime in the therapy of neonatal infections].

Authors:  J de Louvois
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 6.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.